江苏福石生物科技有限公司

About Fushi

Company Profile

company values

Development history

leadership team

Technology platform

Pipeline

news media

Company news

media reports

Join us

Talent concept

office environment

Recruitment information

employee benefits

Staff style

Contact

For the benefit of patients and<br>the cornerstone of new drugs

For the benefit of patients and
the cornerstone of new drugs

Enter Fushi

Jiangsu Fushi Biotechnology Co., Ltd. (hereinafter referred to as: Fushi Bio) was established in December 2021. It was co-founded by Professor He Wei, Academician Li Yadong, and Professor Liu Lei from the School of Pharmacy of Tsinghua University, Professor Ruan Ke from the University of Science and Technology of China, and Dr. Xia Chuanjun, Chairman of Beijing Xiahe Technology.

Fushi Biotechnology relies on multi-modal fragment-based drug discovery platform technology (Fragment-Based Drug Discovery, FBDD), focusing on the fields of cancer and other fields to develop original (first-in-class, FIC) small molecule drugs for diseases with major unmet needs.

Mutual trust unites the team

Tsinghua/HKUST technology founding team; senior industry expert executive team
Tsinghua University of Science and Technology’s backbone doctoral front-line team

Integrate multiple resources

Domestic leading institution angel round financing of RMB 100 million

Academic/Research/Clinical Resources

Relevant support from Anhui Province and Hefei City

Enter Fushi

Technology platform

The FBDD concept emerged at the beginning of this century and has developed significantly in the past 20 years. This model has successfully produced several new drugs approved by the US FDA and dozens of drug candidates in human clinical trials. FBDD has the advantages of strong ability to expand difficult-to-drug targets, high success rate, high novelty, and small required compound library, and has become a drug discovery model that has attracted widespread attention in recent years.
In 2021, two small molecule drugs, Sotorasib (AMG 510) and Asciminib (ABL001), discovered based on FBDD technology, were approved by the FDA.

News

2026-07-09

Fushi Biotechnology’s FS-207 tablets received clinical trial approval from the National Medical Products Administration

In April 2026, FS-207 tablets, a Class 1 innovative drug independently developed by Fushi Biologics, officially received an implicit clinical trial license (IND approval) from the China National Medical Products Administration (NMPA) and is intended to be developed for the treatment of microsatellite instability-high (MSI-H) advanced solid tumors.

Focus on the journey of innovative drugs from the laboratory to clinical practice

Gather a seasoned‑R&D team and cutting‑edge technology platforms to empower efficient new‑drug research and development

Contact

This website uses cookies

This website uses cookies to improve your experience while you navigate through the website. You can choose to opt-out if you wish. For more information, please refer to our 《Cookies》。